Structural insights into binding of small molecule inhibitors to Enhancer of Zeste Homolog 2

Journal of Computer-Aided Molecular Design

Volumn 28, Issue 11, 2014, Pages 1109-1128

  Kalinić, Marko ^a   Zloh, Mire ^b   Erić, Slavica ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

Binding mode elucidation; Enhancer of Zeste Homolog 2; Epigenetic target; Molecular dynamics

Indexed keywords

AMINO ACIDS; BINDING ENERGY; BINDING SITES; COMPLEXATION; LIGANDS; MOLECULES; PROTEINS;

BINDING MODE ELUCIDATION; BINDING MODES; BINDING-SITES; COFACTOR BINDING; ENHANCER OF ZESTE HOMOLOGUE 2; EPIGENETIC TARGET; EPIGENETICS; METHYLTRANSFERASES; SMALL-MOLECULE INHIBITORS; STRUCTURAL INSIGHTS;

MOLECULAR DYNAMICS;

EZH2 PROTEIN, HUMAN; HISTONE; MOLECULAR LIBRARY; POLYCOMB REPRESSIVE COMPLEX 2;

AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; GENETIC EPIGENESIS; HUMAN; MOLECULAR DYNAMICS; MOLECULAR LIBRARY; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; BINDING SITES; EPIGENESIS, GENETIC; HISTONES; HUMANS; MOLECULAR DYNAMICS SIMULATION; POLYCOMB REPRESSIVE COMPLEX 2; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84936760851     PISSN: 0920654X     EISSN: 15734951     Source Type: Journal    
DOI: 10.1007/s10822-014-9788-1     Document Type: Article

References (87)

1. Bannister AJ, Kouzarides T (2011) Regulation of chromatin by histone modifications. Cell Res 21:381-395. doi: 10.1038/cr.2011.22
2. Luger K, Dechassa ML, Tremethick DJ (2012) New insights into nucleosome and chromatin structure: an ordered state or a disordered affair? Nat Rev Mol Cell Biol 13:436-447. doi: 10.1038/nrm3382
3. Arrowsmith CH, Bountra C, Fish PV et al (2012) Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 11:384-400. doi: 10.1038/nrd3674
4. Strahl BD, Allis CD (2000) The language of covalent histone modifications. Nature 403:41-45
5. Gardner KE, Allis CD, Strahl BD (2011) Operating on chromatin, a colorful language where context matters. J Mol Biol 409:36-46. doi: 10.1016/j.jmb.2011.01.040
6. Helin K, Dhanak D (2013) Chromatin proteins and modifications as drug targets. Nature 502:480-488. doi: 10.1038/nature12751
7. Dawson MA, Kouzarides T (2012) Cancer epigenetics: from mechanism to therapy. Cell 150:12-27. doi: 10.1016/j.cell.2012.06.013
8. Jones P (2012) Development of second generation epigenetic agents. MedChemComm 3:135. doi: 10.1039/c1md00199j
9. Rodríguez-Paredes M, Esteller M (2011) Cancer epigenetics reaches mainstream oncology. Nat Med 17:330-339. doi: 10.1038/nm.2305
10. Copeland RA, Moyer MP, Richon VM (2013) Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics. Oncogene 32:939-946. doi: 10.1038/onc.2012.552
11. Copeland RA, Solomon ME, Richon VM (2009) Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov 8:724-732. doi: 10.1038/nrd2974
12. Dillon SC, Zhang X, Trievel RC, Cheng X (2005) The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol 6:227. doi: 10.1186/gb-2005-6-8-227
13. Qian C, Zhou MM (2006) SET domain protein lysine methyltransferases: structure, specificity and catalysis. Cell Mol Life Sci 63:2755-2763. doi: 10.1007/s00018-006-6274-5
14. Nguyen KT, Li F, Poda G et al (2013) Strategy to target the substrate binding site of SET domain protein methyltransferases. J Chem Inf Model 53:681-691. doi: 10.1021/ci300596x
15. Schapira M (2011) Structural chemistry of human SET domain protein methyltransferases. Curr Chem Genomics 5:85-94. doi: 10.2174/1875397301005010085
16. Campagna-Slater V, Mok MW, Nguyen KT et al (2011) Structural chemistry of the histone methyltransferases cofactor binding site. J Chem Inf Model 51:612-623. doi: 10.1021/ci100479z
17. Verma SK, Tian X, La France LV et al (2012) Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2. ACS Med Chem Lett 3:1091-1096. doi: 10.1021/ml3003346
18. Qi W, Chan H, Teng L et al (2012) Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci 109:21360-21365. doi: 10.1073/pnas.1210371110
19. McCabe MT, Ott HM, Ganji G et al (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492:108-112. doi: 10.1038/nature11606
20. Knutson SK, Wigle TJ, Warholic NM et al (2012) A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 8:890-896. doi: 10.1038/nchembio.1084
21. Knutson SK, Warholic NM, Wigle TJ et al (2013) Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci 110:7922-7927. doi: 10.1073/pnas.1303800110
22. Chase A, Cross NCP (2011) Aberrations of EZH2 in cancer. Clin Cancer Res 17:2613-2618. doi: 10.1158/1078-0432.CCR-10-2156
23. Chang C-J, Hung M-C (2012) The role of EZH2 in tumour progression. Br J Cancer 106:243-247. doi: 10.1038/bjc.2011.551
24. Tan J, Yan Y, Wang X et al (2013) EZH2: biology, disease, and structure-based drug discovery. Acta Pharmacol Sin 35:161-174. doi: 10.1038/aps.2013.161
25. Wu H, Zeng H, Dong A et al (2013) Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations. PLoS ONE 8:e83737. doi: 10.1371/journal.pone.0083737
26. Antonysamy S, Condon B, Druzina Z et al (2013) Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain. PLoS ONE 8:e84147. doi: 10.1371/journal.pone.0084147
27. Van Aller GS, Pappalardi MB, Ott HM et al (2013) Long residence time inhibition of EZH2 in activated polycomb repressive complex 2. ACS Chem Biol. doi: 10.1021/cb4008748
28. Tommaso PD, Moretti S, Xenarios I et al (2011) T-coffee: a web server for the multiple sequence alignment of protein and RNA sequences using structural information and homology extension. Nucleic Acids Res 39:W13-W17. doi: 10.1093/nar/gkr245
29. Notredame C, Higgins DG, Heringa J (2000) T-coffee: a novel method for fast and accurate multiple sequence alignment. J Mol Biol 302:205-217. doi: 10.1006/jmbi.2000.4042
30. Xiao B, Jing C, Wilson JR et al (2003) Structure and catalytic mechanism of the human histone methyltransferase SET7/9. Nature 421:652-656. doi: 10.1038/nature01378
31. Couture J-F, Collazo E, Brunzelle JS, Trievel RC (2005) Structural and functional analysis of SET8, a histone H4 Lys-20 methyltransferase. Genes Dev 19:1455-1465. doi: 10.1101/gad.1318405
32. Pettersen EF, Goddard TD, Huang CC et al (2004) UCSF chimera - a visualization system for exploratory research and analysis. J Comput Chem 25:1605-1612. doi: 10.1002/jcc.20084
33. Šali A, Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234:779-815. doi: 10.1006/jmbi.1993.1626
34. Wu H, Min J, Lunin VV et al (2010) Structural biology of human H3K9 methyltransferases. PLoS ONE 5:e8570. doi: 10.1371/journal.pone.0008570
35. Olsson MHM, Søndergaard CR, Rostkowski M, Jensen JH (2011) PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions. J Chem Theory Comput 7:525-537. doi: 10.1021/ct100578z
36. Case DA, Darden TA, Cheatham TE III et al (2012) AMBER 12. University of California, San Francisco
37. Hornak V, Abel R, Okur A et al (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins Struct Funct Bioinform 65:712-725. doi: 10.1002/prot.21123
38. Jorgensen WL, Chandrasekhar J, Madura JD et al (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79:926. doi: 10.1063/1.445869
39. Stacklies W, Xia F, Gräter F (2009) Dynamic allostery in the methionine repressor revealed by force distribution analysis. PLoS Comput Biol 5:e1000574. doi: 10.1371/journal.pcbi.1000574
40. Hamelberg D, Mongan J, McCammon JA (2004) Accelerated molecular dynamics: a promising and efficient simulation method for biomolecules. J Chem Phys 120:11919-11929. doi: 10.1063/1.1755656
41. Wang Y, Harrison CB, Schulten K, McCammon JA (2011) Implementation of accelerated molecular dynamics in NAMD. Comput Sci Discov 4:015002. doi: 10.1088/1749-4699/4/1/015002
42. Hamelberg D, de Oliveira CAF, McCammon JA (2007) Sampling of slow diffusive conformational transitions with accelerated molecular dynamics. J Chem Phys 127:155102. doi: 10.1063/1.2789432
43. De Oliveira CAF, Grant BJ, Zhou M, McCammon JA (2011) Large-scale conformational changes of Trypanosoma cruzi proline racemase predicted by accelerated molecular dynamics simulation. PLoS Comput Biol 7:e1002178. doi: 10.1371/journal.pcbi.1002178
44. Wereszczynski J, McCammon JA (2012) Accelerated molecular dynamics in computational drug design. In: Baron R (ed) Comput Drug Discov Des. Springer, New York, pp 515-524
45. Mücksch C, Urbassek HM (2013) Enhancing protein adsorption simulations by using accelerated molecular dynamics. PLoS ONE 8:e64883. doi: 10.1371/journal.pone.0064883
46. Laskowski RA, MacArthur MW, Moss DS, Thornton JM (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 26:283-291. doi: 10.1107/S0021889892009944
47. Weill N, Rognan D (2010) Alignment-free ultra-high-throughput comparison of druggable protein-ligand binding sites. J Chem Inf Model 50:123-135. doi: 10.1021/ci900349y
48. Kellenberger E, Muller P, Schalon C et al (2006) sc-PDB: an annotated database of druggable binding sites from the protein data bank. J Chem Inf Model 46:717-727. doi: 10.1021/ci050372x
49. Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455-461. doi: 10.1002/jcc.21334
50. - (2013) Marvin 6.0.3. ChemAxon
51. Wang J, Wolf RM, Caldwell JW et al (2004) Development and testing of a general Amber force field. J Comput Chem 25:1157-1174. doi: 10.1002/jcc.20035
52. Wang J, Wang W, Kollman PA, Case DA (2006) Automatic atom type and bond type perception in molecular mechanical calculations. J Mol Graph Model 25:247-260. doi: 10.1016/j.jmgm.2005.12.005
53. Bayly CI, Cieplak P, Cornell W, Kollman PA (1993) A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. J Phys Chem 97:10269-10280. doi: 10.1021/j100142a004
54. Dupradeau F-Y, Pigache A, Zaffran T et al (2010) The R.E.D. tools: advances in RESP and ESP charge derivation and force field library building. Phys Chem Chem Phys 12:7821-7839. doi: 10.1039/C0CP00111B
55. Neese F (2012) ORCA, version 2.9, an ab initio, density functional and semiempirical program package. Max Planck-Institute for Bioinorganic Chemistry: Mülheim a.d., Ruhr, Germany
56. Vanquelef E, Simon S, Marquant G et al (2011) R.E.D. server: a web service for deriving RESP and ESP charges and building force field libraries for new molecules and molecular fragments. Nucleic Acids Res 39:W511-W517. doi: 10.1093/nar/gkr288
57. Frisch MJ, Trucks GW, Schlegel HB et al (2009) Gaussian 09, revision D.01. Gaussian, Inc., Wallingford
58. Schrödinger LLC (2010) The PyMOL molecular graphics system, version 1.3
59. Dunbrack RL, Cohen FE (1997) Bayesian statistical analysis of protein side-chain rotamer preferences. Protein Sci 6:1661-1681. doi: 10.1002/pro.5560060807
60. Schmidtke P, Bidon-Chanal A, Luque FJ, Barril X (2011) MDpocket: open-source cavity detection and characterization on molecular dynamics trajectories. Bioinformatics 27:3276-3285. doi: 10.1093/bioinformatics/btr550
61. Guilloux VL, Schmidtke P, Tuffery P (2009) Fpocket: an open source platform for ligand pocket detection. BMC Bioinform 10:168. doi: 10.1186/1471-2105-10-168
62. Phillips JC, Braun R, Wang W et al (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26:1781-1802. doi: 10.1002/jcc.20289
63. Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14:33-38
64. Koukos PI, Glykos NM (2013) Grcarma: a fully automated task-oriented interface for the analysis of molecular dynamics trajectories. J Comput Chem 34:2310-2312. doi: 10.1002/jcc.23381
65. Williams T, Kelley C (2013) Gnuplot 4.6: an interactive plotting program
66. Miller BR, McGee TD, Swails JM et al (2012) MMPBSA.py: an efficient program for end-state free energy calculations. J Chem Theory Comput 8:3314-3321. doi: 10.1021/ct300418h
67. Kollman PA, Massova I, Reyes C et al (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33:889-897. doi: 10.1021/ar000033j
68. Hayes JM, Archontis G (2012) MM-GB(PB)SA calculations of protein-ligand binding free energies. Mol Dyn Stud Synth Biol Macromol
69. Massova I, Kollman PA (1999) Computational alanine scanning to probe protein-protein interactions: a novel approach to evaluate binding free energies. J Am Chem Soc 121:8133-8143. doi: 10.1021/ja990935j
70. Laio A, Parrinello M (2002) Escaping free-energy minima. Proc Natl Acad Sci 99:12562-12566. doi: 10.1073/pnas.202427399
71. Barducci A, Bussi G, Parrinello M (2008) Well-tempered metadynamics: a smoothly converging and tunable free-energy method. Phys Rev Lett 100:020603. doi: 10.1103/PhysRevLett.100.020603
72. Bonomi M, Branduardi D, Bussi G et al (2009) PLUMED: a portable plugin for free-energy calculations with molecular dynamics. Comput Phys Commun 180:1961-1972. doi: 10.1016/j.cpc.2009.05.011
73. Margueron R, Reinberg D (2011) The polycomb complex PRC2 and its mark in life. Nature 469:343-349. doi: 10.1038/nature09784
74. Sparmann A, van Lohuizen M (2006) Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6:846-856. doi: 10.1038/nrc1991
75. Ciferri C, Lander GC, Maiolica A et al (2012) Molecular architecture of human polycomb repressive complex 2. eLife. doi: 10.7554/eLife.00005
76. Konze KD, Ma A, Li F et al (2013) An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem Biol 8:1324-1334. doi: 10.1021/cb400133j
77. Hou T, Wang J, Li Y, Wang W (2011) Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model 51:69-82. doi: 10.1021/ci100275a
78. Salonen LM, Ellermann M, Diederich F (2011) Aromatic rings in chemical and biological recognition: energetics and structures. Angew Chem Int Ed 50:4808-4842. doi: 10.1002/anie.201007560
79. Leung CS, Leung SSF, Tirado-Rives J, Jorgensen WL (2012) Methyl effects on protein-ligand binding. J Med Chem 55:4489-4500. doi: 10.1021/jm3003697
80. Perola E, Charifson PS (2004) Conformational analysis of drug-like molecules bound to proteins: an extensive study of ligand reorganization upon binding. J Med Chem 47:2499-2510. doi: 10.1021/jm030563w
81. Hao M-H, Haq O, Muegge I (2007) Torsion angle preference and energetics of small-molecule ligands bound to proteins. J Chem Inf Model 47:2242-2252. doi: 10.1021/ci700189s
82. Sneeringer CJ, Scott MP, Kuntz KW et al (2010) Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci 107:20980-20985. doi: 10.1073/pnas.1012525107
83. McCabe MT, Graves AP, Ganji G et al (2012) Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci 109:2989-2994. doi: 10.1073/pnas.1116418109
84. Majer CR, Jin L, Scott MP et al (2012) A687V EZH2 is a gain-of-function mutation found in lymphoma patients. FEBS Lett 586:3448-3451. doi: 10.1016/j.febslet.2012.07.066
85. Copeland RA (2013) Molecular pathways: protein methyltransferases in cancer. Clin Cancer Res 19:6344-6350. doi: 10.1158/1078-0432.CCR-13-0223
86. Garapaty-Rao S, Nasvechuk C, Gagnon A et al (2013) Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chem Biol. doi: 10.1016/j.chembiol.2013.09.013
87. Nasveschuk CG, Gagnon A, Garapaty-Rao S et al (2014) Discovery and optimization of tetramethylpiperidinyl benzamides as inhibitors of EZH2. ACS Med Chem Lett. doi: 10.1021/ml400494b